FDA-approved · Cash-pay · Ships to your door
Zepbound® pen prescription online for weight loss
Access FDA-approved Zepbound® (tirzepatide) — the dual GIP / GLP-1 receptor agonist from Eli Lilly — through a US-licensed clinician if it's right for you.
- FDA-approved for chronic weight management in eligible adults
- Once-weekly dual GIP / GLP-1 subcutaneous injection
- Reviewed online and shipped from a US-licensed pharmacy
- Flat cash-pay pricing — no insurance billing
Cash-pay price
$1,069/mo
Cash-pay only; not billed to insurance. Eligibility determined by a US-licensed clinician.
About
What is Zepbound®?
Zepbound® is the FDA-approved tirzepatide product from Eli Lilly and Company, indicated for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbidity. Tirzepatide is a dual GIP and GLP-1 receptor agonist, delivered as a once-weekly subcutaneous injection.
Pallas dispenses Zepbound® through US-licensed pharmacies on a cash-pay basis. Insurance routing is not currently supported. Eligibility is determined by a licensed clinician based on your intake and clinical history.
Pivotal trial · SURMOUNT-1
Participants on the 15 mg dose of tirzepatide lost an average of ~20.9% of body weight at 72 weeks alongside lifestyle intervention.
Source: New England Journal of Medicine, 2022. Outcome reflects the cited trial of the FDA-approved product and the conditions studied. Individual results may differ.
Dosing
Dosing & schedule
Zepbound® uses a titration schedule that gradually increases the dose to reduce side effects. Your clinician selects the right maintenance dose based on your response and tolerability.
- Weeks 1–42.5 mg once weekly — starting dose
- Weeks 5–85 mg once weekly
- Weeks 9+Increased every 4 weeks as tolerated, up to 15 mg weekly maintenance
How it works
01
Complete your online intake
A short, clinical questionnaire — about 5 minutes. Honest answers help your clinician give the best recommendation.
02
A US-licensed clinician reviews
A licensed clinician in your state reviews your intake and decides whether a prescription is clinically appropriate. They may message you for follow-up if needed.
03
Ships from a US-licensed pharmacy
If approved, your prescription is dispensed by a US-licensed pharmacy and shipped to your door in discreet packaging.
Safety
Important safety information
GLP-1 medications can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and — based on animal studies — a possible risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications. Always disclose your full medical history to your clinician. Zepbound®'s full FDA-approved prescribing information, including its boxed warning, is available from Eli Lilly and at the link below.
FAQ
Common questions
Zepbound® is the brand name for FDA-approved tirzepatide, manufactured by Eli Lilly for chronic weight management. Tirzepatide activates both the GIP and GLP-1 receptors, and is delivered as a once-weekly subcutaneous injection.
Zepbound® is $1,069/month on Pallas — billed flat, cash-pay, with no insurance routing. The price covers a 28-day supply shipped from a US-licensed pharmacy. For comparison, Zepbound®'s pharmacy list price without insurance is around $1,300/month, and Eli Lilly offers lower-dose self-pay vials through LillyDirect.
In the SURMOUNT-1 pivotal trial, participants on the 15 mg dose of tirzepatide lost an average of about 20.9% of body weight at 72 weeks alongside lifestyle intervention (New England Journal of Medicine, 2022). Individual results vary, and this outcome reflects the FDA-approved product under the conditions studied.
The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal discomfort — usually most noticeable during dose increases and easing over time. Rare but serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors based on animal studies. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use it. Review the full prescribing information and disclose your medical history to your clinician.
Tirzepatide is the active ingredient; Zepbound® is the FDA-approved brand of tirzepatide for weight management (Mounjaro® is the same molecule approved for type 2 diabetes). So FDA-approved Zepbound® is tirzepatide. Compounded tirzepatide, however, is not the same as Zepbound® — it is not FDA-approved, not a generic, and has not been evaluated by the FDA.
Zepbound® contains tirzepatide (a dual GIP/GLP-1 agonist made by Eli Lilly), while Wegovy® contains semaglutide (a GLP-1 agonist made by Novo Nordisk). Both are FDA-approved for chronic weight management. They differ in molecule, manufacturer, and clinical trial results — your clinician can help determine which is more appropriate for you.
No. Pallas is a cash-pay service. Insurance is not currently billed for any medication on the platform. Pricing is flat and disclosed up front — what you see is what you pay.
Complete a short clinical intake — usually under 5 minutes. A US-licensed clinician reviews your history, decides whether a prescription is clinically appropriate, and (if approved) sends it to a US-licensed pharmacy that ships directly to you in discreet packaging.
Yes. There is no long-term contract. You can pause or cancel your subscription at any time from your patient portal. Refunds are handled on a case-by-case basis per our terms.
Start your visit
